Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

January 18, 2018April 5, 2019

Givinostat Phase 3 Trial Recruiting Duchenne Patients in North America, Europe

News

A global Phase 3 trial of givinostat — an investigational treatment aiming to boost the muscle regeneration capacity in Duchenne muscular dystrophy patients — is recruiting participants across North America ... Read more

January 15, 2018January 15, 2018

Pharma Giants Form UK-Based ‘Project Hercules’ to Generate Evidence for DMD Treatments

News

Seven pharmaceutical companies are banding together to sponsor Project Hercules — an initiative that addresses evidence generation for Duchenne muscular dystrophy (DMD) treatments. The project, led by the non-profit ... Read more

January 12, 2018

Duchenne May Affect the Brain Too, Study Contends

News

Researchers have found that Duchenne muscular dystrophy patients usually have simultaneous neurological disorders or abnormalities, including epilepsy. Particularly, those who had epilepsy also had the neurodevelopmental condition attention deficit ... Read more

January 10, 2018

Working Muscle Grown from Skin Sample, Raising Hopes for Regenerative Treatments

News

Researchers have succeeded in growing working muscle tissue from a skin sample — a feat that until recently was viewed as science fiction. Although the lab-grown muscle was not as ... Read more

December 1, 2017

Capricor Set to Launch Phase 2 Trial of Cell Therapy CAP-1002 in Advanced DMD Patients

News

Capricor Therapeutics has received a green light from the U.S. Food and Drug Administration to launch a Phase 2 study of CAP-1002 cell therapy in children and adults with ... Read more

November 20, 2017

Capricor’s CAP-1002 Does More Than Repair DMD Hearts, Study Finds

News

A one-time infusion of Capricor Therapeutics’ heart progenitor cell therapy CAP-1002 improved heart muscle function and reduced tissue scarring in a small group of patients with Duchenne muscular dystrophy. ... Read more

November 3, 2017

Bionano Genomics Platform May Shorten Time to Duchenne Diagnosis, Researchers Suggest

News

A new method using DNA isolated from a blood sample was far more sensitive in detecting large mutations causing Duchenne muscular dystrophy than currently used genetic diagnostics tools, according ... Read more

October 12, 2017

Nerve Control of Breathing Overactive in Duchenne Mice, Suggesting Potential Treatment Target

News

Mice with Duchenne muscular dystrophy compensate for the weakness in their breathing muscles by sending stronger signals to the nerves controlling the diaphragm, according to scientists at the University ... Read more

October 4, 2017October 4, 2017

Sarepta on ‘Mission’ It Intends to Accomplish and Soon, CEO Doug Ingram Says in Interview

News

With one exon-skipping therapy — Exondys 51 (eteplirsen) — approved for Duchenne muscular dystrophy (DMD) and others in clinical trials, it’s easy to envision Sarepta Therapeutics as the “exon-skipping ... Read more

October 4, 2017October 4, 2017

New Trial for Exondys 51 Yet to Come but Goal Is to Embrace More Duchenne Patients, Sarepta Says in Interview

News

Parents of boys with Duchenne muscular dystrophy (DMD) as well as patient advocacy groups are praising the recent approval of Sarepta Therapeutics‘ Exondys 51 (eteplirsen) to treat the disease. But the ... Read more

Pin It on Pinterest